Pfizer trimming daily weight loss pill Danuglipron after liver injury

Pfizer Monday stated to finish the development of his experimental Daily Weight Loss Pills After the patient, a liver injury occurred, which was potentially caused by the drug during the test.

The patient did not experience any symptoms associated with the liver or side effects, Pfizer spokesman said in a statement. They added that the patient’s liver enzymes were “quickly restored” after they stopped taking pills, which is a GLP-1 oral drug called Danuglipron. The statement implies that the patient’s liver enzymes have been raised, often often indicates damage to cells in the body and there is problem This was due to some other obesity medicines.

The case happened in the trial, which quickly increased the dose of pills over a short period of time, the press secretary said. The PFIZER decision to stop the development of the drug happened after “considering a set of information, including all clinical data obtained for Danuglipron and a recent contribution from regulators,” the release reports.

“While we are disappointed with the cessation of Danuglipron development, we still strive to evaluate and promote promising programs, seeking to involve new innovative medicines,” Dr. Chris Boshoff, Chief Scientist Pfizer said in the release. He added that the company still develops other medicines for weight loss.

The announcement adds a number of setbacks in the company’s application to win a piece of boom market for the GLP-1, which mimic certain bowel hormones to knock down the appetite and regulate blood sugar. Pfizer – Among multiple drug manufacturers to bring more convenient weight loss medications to space where weekly injections prevail Eli Lily and Novo nordisk.

Some analysts at Wall Street expect the GLP-1 industry to the early 2030s will cost more than $ 150 billion. Oral GLP-1 can grow to make up $ 50 billion from total, while injections will explain the rest Some analysts’ estimates.

This is not the first set of Pfizer with Danuglipron, in particular. Campaign stopped In December 2023, in December 2023, after the patients had drug problems, on average, the study.

But pfizer seemed Start conducting research In the second half of the year to assess several doses of the pill.

Despite the decision to trim the drug, Pfizer said on Monday that these studies reached key goals and confirmed a certain form and dose of pills with the potential to ensure “competitive efficiency and tolerability” in lawsuits.

The company also noted that the speed Increased liver enzymes In people who took Danuglipron corresponds to the approved GLP-1 drug, which is based on safety database with more than 1400 patients who took Pfizer tablets.

In June 2023, Pfizer abandoned obesity tablets a day after patients who came this drug had a higher level of liver enzymes in the medium -stage test. Since then, investors have been treating the company in the GLP-1 space.

However, Pfizer has Other experimental Obesity preparations in its pipeline in the early stages of development, which seem to work differently than its already stopped treatments. This includes an oral drug that blocks another intestinal hormone called GIPR, which entered the second stage last year, and additional oral GLP-1 at the first stage.

Pfizer believes that GIPR drugs may be more effective and easier to tolerate patients, said former chief scientific director Mikael Dolsten, who has left the campaign since then, investors said in October. He added that “there are so many applications for the GLP-1”.

Danuglipron Pfizer promotes weight loss, focusing on the GLP-1, and this is also how to injure weight Novo Nordisk Wegovy and Diabetes Treatment of Azics. Eli Lily Zepbound and Diabetes are shot by Mounjaro Target GLP-1, but also activate another intestinal hormone called GIP.

The only GLP-1 lips approved by the Powered and Medicine Office so far vendor In 2024.

An ad pfizer on Monday comes when the company restores its foundation and Restores its stock price After the rapid decline of his sad business. Pfizer is betting on its cancer pipeline to provide long -term growth, but emphasized that obesity is a key accent.